ProCE Banner Activity

Key Questions on Emerging Treatments for Hepatitis Delta

Clinical Thought
Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Released: March 23, 2022

Expiration: March 22, 2023

Share

Faculty

Heiner Wedemeyer

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Roche, and Vir; has received funds for research support from AbbVie, Biotest, Gilead Sciences, MSD/Merck, and Roche; and has served as a clinical trials investigator for AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Novartis, and Vir.